Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities

Zyryanov, S. K.; Бутранова, О. И.; Гайдай, Д. С.; Kryshen, Kirill

doi:10.26442/00403660.2021.01.200551

Cited by 5 publications

(1 citation statement)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Favipiravir is a prodrug that converts to an active metabolite with broad-spectrum activity developed to treat influenza and used against Ebola (9,10). Published clinical trials on the adult population reported benefits in patients diagnosed with COVID-19 (11); however, the data were not conclusive.…”

Section: Introductionmentioning

confidence: 99%

A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19

et al. 2022

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) affects the pediatric population. Objectives: Due to limited data, this study aimed to evaluate the safety and efficacy of favipiravir in the hospitalized pediatric population diagnosed with COVID-19. Methods: The present retrospective cohort study was conducted on pediatric patients aged 1 - 18 years with a diagnosis of COVID-19 admitted to Mofid Children’s Hospital, Tehran, Iran. Favipiravir was administrated at a dose of 60 mg/kg/day (max: 3200 mg/day) on the first day and then 23 mg/kg/day (max: 1200 mg/day) for 7 to 14 days. The patients were evaluated regarding the need for invasive mechanical ventilation, intensive care unit admission, duration of hospital stay, and mortality. Safety was measured by the occurrence of related adverse drug reactions (ADRs). Results: A total of 95 patients were included in the study. Favipiravir was administered to 25 patients. The need for invasive mechanical ventilation was reported in 4 (16.00%) and 11 (15.71%) patients in the favipiravir and control groups, respectively (P = 1.000). The median duration of hospital stays was significantly higher in patients who received favipiravir than in the controls (P = 0.002). No difference was observed in the mortality rate (P = 0.695). The ADRs, including decreased appetite, hypotension, and chest pain, were more prevalent in patients who received favipiravir than in the controls (P < 0.05). Conclusions: The administration of favipiravir in the pediatric population is associated with higher ADR occurrence with no positive effect on the need for invasive mechanical ventilation, hospital stay, and mortality. Further randomized controlled trials are necessary for better judgment.

show abstract

Section: Introductionmentioning

confidence: 99%

A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

Changes in tactics of COVID-19 drug therapy

Zubtsova

2022

Tambov Medical Journal

View full text Add to dashboard Cite

The severity of the new coronavirus infection COVID-19 stated the difficult task of developing treatments for this previously unknown disease to the medical community. The level of knowledge about the nature of the infection also influences the development of new treatment algorithms. We consider the formation stages of drug therapy of coronavirus infection as research by Russian and foreign medical communities shows previous treatment experience of diseases caused by other coronaviruses representatives. Based on the results and experience of using different groups of drugs, clinical recommendations for the treatment of COVID-19 have been formed. The purpose of the research: to trace the stages of approaches and tactics of drug treatment of a new coronavirus infection. The material for this research is the data obtained in the analysis of modern foreign and national literature on this problem. Conclusion: despite the fact that the COVID-19 epidemic has been spreading around the world for several years, there is still no “gold standard” treatment with 100% effectiveness. In this regard, the issue of forming a competent approach to COVID-19 therapy in order to reduce mortality, increase the effectiveness and safety of the treatment remains relevant today.

show abstract

The mechanisms of anti-inflammatory action of enisamium iodide

Федотчева

Semeikin

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. The role of cyclooxygenases (COX-1 and/or COX-2), transcription nuclear factor NF-B, anti-inflammatory cytokines TGF1b, IL-4, IL-10 and pro-inflammatory cytokines IL-1, IL-6 were studied to substantiate the expediency of antiviral agent enisamium iodide (Nobazit) using to regulate key inflammatory components in acute respiratory infections, IL-8, TNF-alpha in the realization of the pharmacological activity of this drug. Materials and methods. Gene expression was determined by real-time RT-PCR, the concentration of interleukins was determined by ELISA, and the viability of peripheral blood mononuclear cells (PBMC) was assessed by the MTT spectrophotometric method. The chemiluminescence method was used to assess PBMC oxidant activity. Results. Enisamium iodide (10 M) reduced mRNA levels of COX-1, COX-2, NF-B, TGF1b, IL-1, IL-6 in stimulated PBMC of healthy donors by an average of 48% (p0.05). At 5 times higher concentration, 50 M, enisamium iodide suppressed the expression of these genes by an average of 43% (p0.05). At a concentration of 100 M, enisamium iodide reduced the expression of COX-2, TGF1b, IL-1, IL-6 by an average of 47% (p0.05). At a concentration of 10 M, enisamium iodide stimulated the secretion of IL-10 by mononuclear cells by 1.2 times, p0.05. The tested drug at a concentration of 50 M did not affected on the concentration of IL-1, IL-4, IL-8 and TNF-alpha, but significantly stimulated the production of IL-10 by 1.5 times, p0.05. The chemiluminescence method revealed that enisamium iodide in the entire concentration range (10100 M) does not reduce the viability of macrophages, but inhibits their oxidative activity (maximum value of CL intensity) by an average of 55% (p0.05). Conclusion. The anti-inflammatory effect of enisamium iodide at a concentration of 10 M may be associated with inhibition of the expression of COX-1, 2, NF-B, IL-1, IL-6, TGF1b and an increase in the expression and production of IL-10. An additional contribution to the anti-inflammatory activity of enisamium iodide is made by its antioxidant and antiradical activity. The absence of the effect of enisamium iodide (10100 M) on the viability of PBMC indicates its safety for the cells of the immune system and the expediency of using it to suppress inflammatory reactions in acute respiratory infections, restore the quality of life of patients and the possibility of using Nobazit as an effective agent for treatment of these infections of various etiologies.

show abstract

Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities

Cited by 5 publications

References 86 publications

A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19

A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19

Changes in tactics of COVID-19 drug therapy

The mechanisms of anti-inflammatory action of enisamium iodide

Contact Info

Product

Resources

About